Seminars in Radiation Oncology
Volume 20, Issue 1 , Pages 30-44 , January 2010

Hodgkin Lymphoma Across the Age Spectrum: Epidemiology, Therapy, and Late Effects

  • Angela Punnett, MD, FRCPC

      Affiliations

    • Division of Hematology and Oncology, Hospital for Sick Children, Toronto, ON
    • ,
  • Richard W. Tsang, MD, FRCPC

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, The University of Toronto, Toronto, ON
    • ,
  • David C. Hodgson, MD, MPH, FRCPC

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, The University of Toronto, Toronto, ON
    • Corresponding Author InformationAddress reprint requests to David C. Hodgson, MD, MPH, FRCPC, Department of Radiation Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, ON, Canada M5G 2M9

References 

  1. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008;111:2977–2983
  2. Donaldson SS, Kaplan HS. Complications of treatment of Hodgkin's disease in children. Cancer Treat Rep. 1982;66:977–989
  3. Mauch PM, Weinstein H, Botnick L. An evaluation of long-term survival and treatment complications in children with Hodgkin's disease. Cancer. 1983;51:925–932
  4. Ferme C, Eghbali H, Meerwaldt JH. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357:1916–1927
  5. Ries LAG, Eisner MP, Kosary CL. SEER cancer statistics review, 1975-2002. http://seer.cancer.gov/csr/1975_2002/
  6. Armstrong AA, Alexander FE, Cartwright R. Epstein–Barr virus and Hodgkin's disease: Further evidence for the three disease hypothesis. Leukemia. 1998;12:1272–1276
  7. Andersson J. Epstein–Barr virus and Hodgkin's lymphoma. Herpes. 2006;13:12–16
  8. Jarrett RF. Viruses and Hodgkin's lymphoma. Ann Oncol. 2002;13(suppl 1):23–29
  9. Grufferman S, Delzell E. Epidemiology of Hodgkin's disease. Epidemiol Rev. 1984;6:76–106
  10. Spitz MR, Sider JG, Johnson CC. Ethnic patterns of Hodgkin's disease incidence among children and adolescents in the United States, 1973-82. J Natl Cancer Inst. 1986;76:235–239
  11. Cleary SF, Link MP, Donaldson SS. Hodgkin's disease in the very young. Int J Radiat Oncol Biol Phys. 1994;28:77–83
  12. Parkes SE, Coad NA, Muir KR. Hodgkin's disease in children in the West Midlands, 1957-86: A large population-based study. Pediatr Hematol Oncol. 1994;11:471–486
  13. Alexander FE, Jarrett RF, Lawrence D. Risk factors for Hodgkin's disease by Epstein–Barr virus (EBV) status: Prior infection by EBV and other agents. Br J Cancer. 2000;82:1117–1121
  14. Glaser SL, Lin RJ, Stewart SL. Epstein–Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data. Int J Cancer. 1997;70:375–382
  15. Flavell KJ, Biddulph JP, Powell JE. South Asian ethnicity and material deprivation increase the risk of Epstein–Barr virus infection in childhood Hodgkin's disease. Br J Cancer. 2001;85:350–356
  16. Westergaard T, Melbye M, Pedersen JB. Birth order, sibship size and risk of Hodgkin's disease in children and young adults: A population-based study of 31 million person-years. Int J Cancer. 1997;72:977–981
  17. Chang ET, Zheng T, Weir EG, et al. Childhood social environment and Hodgkin's lymphoma: New findings from a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13:1361–1370
  18. Asano N, Yamamoto K, Tamaru J. Age-related Epstein–Barr virus (EBV)-associated B-cell lymphoproliferative disorders: Comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood. 2009;113:2629–2636
  19. Engert A, Ballova V, Haverkamp H. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23:5052–5060
  20. MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res. 1966;26:1189–1201
  21. Carbone A, Gloghini A. AIDS-related lymphomas: From pathogenesis to pathology. Br J Haematol. 2005;130:662–670
  22. Bierman PJ, Vose JM, Langnas AN. Hodgkin's disease following solid organ transplantation. Ann Oncol. 1996;7:265–270
  23. Rowlings PA, Curtis RE, Passweg JR. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol. 1999;17:3122–3127
  24. Smitten AL, Simon TA, Hochberg MC. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R45
  25. Landgren O, Engels EA, Pfeiffer RM. Autoimmunity and susceptibility to Hodgkin lymphoma: A population-based case-control study in Scandinavia. J Natl Cancer Inst. 2006;98:1321–1330
  26. Goldin LR, Pfeiffer RM, Gridley G. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004;100:1902–1908
  27. Lister TA, Crowther D, Sutcliffe SB. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–1636
  28. Ng AK, Bernardo MV, Silver B. Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2005;61:175–184
  29. Wirth A, Seymour JF, Hicks RJ. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002;112:262–268
  30. Van Den Bossche B, Lambert B, De Winter F. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun. 2002;23:1079–1083
  31. Smith RS, Chen Q, Hudson MM. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol. 2003;21:2026–2033
  32. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease (International Prognostic Factors Project on Advanced Hodgkin's Disease). N Engl J Med. 1998;339:1506–1514
  33. Bayle-Weisgerber C, Lemercier N, Teillet F. Hodgkin's disease in children (Results of therapy in a mixed group of 178 clinical and pathologically staged patients over 13 years). Cancer. 1984;54:215–222
  34. Gehan EA, Sullivan MP, Fuller LM. The intergroup Hodgkin's disease in children (A study of stages I and II). Cancer. 1990;65:1429–1437
  35. Donaldson SS, Glatstein E, Rosenberg SA. Pediatric Hodgkin's disease (II. Results of therapy). Cancer. 1976;37:2436–2447
  36. Devita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73:881–895
  37. Longo DL, Young RC, Wesley M. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986;4:1295–1306
  38. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol. 1987;5:742–749
  39. Jenkin D, Doyle J, Berry M. Hodgkin's disease in children: Treatment with MOPP and low-dose, extended field irradiation without laparotomy (Late results and toxicity). Med Pediatr Oncol. 1990;18:265–272
  40. Oberlin O, Leverger G, Pacquement H. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10:1602–1608
  41. Bonadonna G, Zucali R, Monfardini S. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–259
  42. Canellos GP, Anderson JR, Propert KJ. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–1484
  43. Duggan DB, Petroni GR, Johnson JL. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol. 2003;21:607–614
  44. Santoro A, Bonadonna G, Valagussa P. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5:27–37
  45. NCCN: The NCCN clinical practice guidelines in oncology. Hodgkin's Disease/Lymphoma. http://www.nccn.org
  46. Engert A, Dreyling M. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(suppl 2):ii65–ii66
  47. Press OW, LeBlanc M, Lichter AS. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001;19:4238–4244
  48. Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38(suppl 4):S107–S113
  49. Diehl V, Fuchs M. Early, intermediate and advanced Hodgkin's lymphoma: Modern treatment strategies. Ann Oncol. 2007;18(suppl 9):ix71–ix79
  50. Landman-Parker J, Pacquement H, Leblanc T. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18:1500–1507
  51. Donaldson SS, Link MP, Weinstein HJ. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol. 2007;25:332–337
  52. Nachman JB, Sposto R, Herzog P. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765–3771
  53. Schellong G, Potter R, Bramswig J. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90 (The German-Austrian Pediatric Hodgkin's Disease Study Group). J Clin Oncol. 1999;17:3736–3744
  54. Dorffel W, Luders H, Ruhl U. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr. 2003;215:139–145
  55. Engert A, Schiller P, Josting A. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21:3601–3608
  56. Bonadonna G, Bonfante V, Viviani S. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol. 2004;22:2835–2841
  57. Eich H, Mueller R, Engert A. Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles of ABVD in early stage Hodgkin's lymphoma: Interim analysis of the German Hodgkin Study Group Trial HD10. Int J Radiat Oncol Biol Phys. 2005;63(suppl 1):S1
  58. Hodgson DC, Hudson MM, Constine LS. Pediatric Hodgkin lymphoma: Maximizing efficacy and minimizing toxicity. Semin Radiat Oncol. 2007;17:230–242
  59. Tebbi CK, Mendenhall N, London WB. Treatment of stage I, IIA, IIIA(1) pediatric Hodgkin's disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer. 2006;46:198–202
  60. Meyer RM. Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?. Eur J Haematol Suppl. 2005;66:115–120
  61. Yahalom J. Don't throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin's lymphoma. J Clin Oncol. 2006;24:544–548
  62. Meyer RM, Gospodarowicz MK, Connors JM. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634–4642
  63. Thomas J, Ferme C, Noordijk EM. Results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma. Haematologica. 2007;92:27
  64. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Cin Oncol. 2006;24:3128–3135
  65. Gobbi PG, Levis A, Chisesi T. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23:9198–9207
  66. Aleman BM, Raemaekers JM, Tirelli U. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003;348:2396–2406
  67. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431–3439
  68. Ferme C, Mounier N, Casasnovas O, et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: A study by the Groupe d'Etude des Lymphomes de 1'Adulte (GELA). Blood. 2006;107:4635–4642
  69. Diehl V, Franklin J, Pfreundschuh M. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386–2395
  70. Diehl V, Schiller P, Engert A. Results of the Third Interim Analysis of the HD12 Trial of the GHSG: 8 courses of escalated BEACOPP versus 4 escalated and 4 baseline courses of BEACOPP with or without additive radiotherapy for Advanced Stage Hodgkin's Lymphoma [abstract]. Blood. 2003;102:85
  71. Diehl V, Haverkamp H, Mueller RP, et al. Eight cycles of BEACOPP Escalated compared with 4 cycles of BEACOPP Baseline with or without radiotherapy in patients with advanced stage Hodgkin Lymphoma (HL): Final analysis of the randomized HD12 trial of the German Hodgkin Study Group (GHSG). Blood (ASH Annual Meeting Abstracts). 2008;112:1558
  72. Ruhl U, Albrecht MR, Lueders H, et al. The German multinational GPOH-HD95 trial: Treatment results and analysis of failures in pediatric Hodgkins disease using combination chemotherapy with and without radiation. In J Radiat Oncol Biol Phys. 2004;60:S131
  73. Weiner MA, Leventhal B, Brecher ML. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol. 1997;15:2769–2779
  74. Hudson MM, Krasin M, Link MP. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol. 2004;22:4541–4550
  75. Cosset JM, Ferme C, Eghbali H. MOPP/ABV hybrid and irradiation in unfavourable supradiaphragmatic clinical stages I–II Hodgkin's lymphoma: Preliminary results of the EORTC-GELA H8-U randomized trial (# 20931) in 995 patients. Leuk Lymphoma. 2001;42:12
  76. Diehl V, Brillant C, Engert A. Reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD 10 trial of the GHSG. Eur J Haematol. 2004;73(suppl 65):37
  77. Horning SJ, Hoppe RT, Breslin S. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630–637
  78. Radford JA, Rohatiner AZ, Ryder WD. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol. 2002;20:2988–2994
  79. Sieber M, Bredenfeld H, Josting A. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21:1734–1739
  80. Ferme C, Sebban C, Hennequin C. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: Results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood. 2000;95:2246–2252
  81. Diehl V, Loeffler M, Pfreundschuh M. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease (German Hodgkins' Study Group (GHSG)). Ann Oncol. 1995;6:901–910
  82. Loeffler M, Brosteanu O, Hasenclever D. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease (International Database on Hodgkin's Disease Overview Study Group). J Clin Oncol. 1998;16:818–829
  83. Fabian CJ, Mansfield CM, Dahlberg S. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease (A Southwest Oncology Group randomized study). Ann Intern Med. 1994;120:903–912
  84. Eich HT, Staar S, Gossmann A. The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): A quality assurance program based on a multidisciplinary panel reviewing all patients' imaging. Am J Clin Oncol. 2004;27:279–284
  85. Schwartz CL. Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl. 2005;66:55–62
  86. Dann EJ, Bar-Shalom R, Tamir A. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood. 2007;109:905–909
  87. Kelly KM, Hutchinson RJ, Sposto R. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: Preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol. 2002;13(suppl 1):107–111
  88. Advani R, Maeda L, Lavori P. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol. 2007;25:3902–3907
  89. Guay C, Lepine M, Verreault J. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med. 2003;44:1225–1231
  90. Naumann R, Vaic A, Beuthien-Baumann B. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001;115:793–800
  91. de Wit M, Bohuslavizki KH, Buchert R. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol. 2001;12:29–37
  92. Hutchings M, Loft A, Hansen M. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–59
  93. Gallamini A, Rigacci L, Merli F. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91:475–481
  94. Gallamini A, Hutchings M, Rigacci L. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–3752
  95. Picardi M, De Renzo A, Pane F. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48:1721–1727
  96. Kaplan HS, Rosenberg SA. The treatment of Hodgkin's disease. Med Clin North Am. 1966;50:1591–1610
  97. Girinsky T, van der Maazen R, Specht L. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol. 2006;79:270–277
  98. Shahidi M, Kamangari N, Ashley S. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol. 2006;78:1–5
  99. Campbell BA, Voss N, Pickles T. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: A question of field size. J Clin Oncol. 2008;26:5170–5174
  100. Tirelli U, Serraino D, Zagonel V. Hodgkin's disease in patients 70 years of age or more (A retrospective EORTC Lymphoma Group Study). Cancer Invest. 1990;8:643–644
  101. Klimm B, Diehl V, Engert A. Hodgkin's lymphoma in the elderly: A different disease in patients over 60. Oncology (Williston Park). 2007;21:982–990discussion 990, 996, 998, passim
  102. Stats NCISEaERF. http://seer.cancer.gov/faststats/selections.phpAccessed April 28, 2009
  103. Ballova V, Ruffer JU, Haverkamp H. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16:124–131
  104. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE. Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer Registry. Eur J Cancer. 2005;41:1051–1057
  105. Kolstad A, Nome O, Delabie J. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma. 2007;48:570–576
  106. Coiffier B. The challenges of Hodgkin lymphoma in the elderly. Oncology (Williston Park). 2008;22:1388,1393
  107. Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: A clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol. 2009;71:222–232
  108. Levis A, Anselmo AP, Ambrosetti A. Survival after Hodgkin lymphoma: Causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer. 2009;115:1680–1691
  109. Favier O, Heutte N, Stamatoullas-Bastard A, et al. Survival after Hodgkin lymphoma: Causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer. 2009;115:1680–1691
  110. Pihkala J, Saarinen UM, Lundstrom U. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer. 1996;32A:97–103
  111. Polliack A. Late therapy-induced cardiac and pulmonary complications in cured patients with Hodgkin's disease treated with conventional combination chemoradiotherapy. Leuk Lymphoma. 1995;15:7–10
  112. Lipshultz SE, Colan SD, Gelber RD. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–815
  113. Kremer LC, van Dalen EC, Offringa M. Frequency and risk factors of anthracycline-induced clinical heart failure in children: A systematic review. Ann Oncol. 2002;13:503–512
  114. Lipshultz SE, Lipsitz SR, Mone SM. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–1743
  115. Donaldson SS, Hudson MM, Lamborn KR. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. J Clin Oncol. 2002;20:3081–3087
  116. Hodgson DC, Gilbert ES, Dores GM. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25:1489–1497
  117. Boice JD. Radiation and breast carcinogenesis. Med Pediatr Oncol. 2001;36:508–513
  118. van Leeuwen FE, Klokman WJ, Stovall M. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95:971–980
  119. Ralleigh G, Given-Wilson R. Breast cancer risk and possible screening strategies for young women following supradiaphragmatic irradiation for Hodgkin's disease. Clin Radiol. 2004;59:647–650
  120. US Preventive Services Task Force. Screening for colorectal cancer: Recommendation and rationale. Ann Intern Med. 2002;137:129–131
  121. Landier W. Children's Oncology Group Long-Term Follow-Up Program Resource Guide. Children's Oncology Group. 2007;
  122. Travis LB, Hill D, Dores GM. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428–1437
  123. Bhatia S, Yasui Y, Robison LL. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386–4394
  124. Constine LS, Donaldson SS, McDougall IR. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer. 1984;53:878–883
  125. Sklar C, Whitton J, Mertens A. Abnormalities of the thyroid in survivors of Hodgkin's disease: Data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227–3232
  126. de Bruin JP, Dorland M, Spek ER. Age-related changes in the ultrastructure of the resting follicle pool in human ovaries. Biol Reprod. 2004;70:419–424
  127. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: The Stanford experience. Int J Radiat Oncol Biol Phys. 1990;19:873–880
  128. van den Berg H, Furstner F, van den Bos C. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin's disease. Pediatr Blood Cancer. 2004;42:210–215
  129. Bramswig JH, Heimes U, Heiermann E. The effects of different cumulative doses of chemotherapy on testicular function (Results in 75 patients treated for Hodgkin's disease during childhood or adolescence). Cancer. 1990;65:1298–1302
  130. Hobbie WL, Ginsberg JP, Ogle SK. Fertility in males treated for Hodgkin's disease with COPP/ABV hybrid. Pediatr Blood Cancer. 2005;44:193–196
  131. Haukvik UK, Dieset I, Bjoro T. Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol. 2006;17:1428–1433
  132. Bonadonna G, Santoro A, Viviani S. Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens. Arch Toxicol Suppl. 1984;7:140–145
  133. Behringer K, Breuer K, Reineke T. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005;23:7555–7564
  134. Brusamolino E, Baio A, Orlandi E. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res. 2006;12:6487–6493
  135. Hodgson DC, Pintilie M, Gitterman L. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25:11–15

PII: S1053-4296(09)00068-X

doi: 10.1016/j.semradonc.2009.09.006

Seminars in Radiation Oncology
Volume 20, Issue 1 , Pages 30-44 , January 2010

Article Tools

* Image Usage & Resolution